JP2022513490A - 遺伝子編集線維芽細胞の治療的使用 - Google Patents

遺伝子編集線維芽細胞の治療的使用 Download PDF

Info

Publication number
JP2022513490A
JP2022513490A JP2021534228A JP2021534228A JP2022513490A JP 2022513490 A JP2022513490 A JP 2022513490A JP 2021534228 A JP2021534228 A JP 2021534228A JP 2021534228 A JP2021534228 A JP 2021534228A JP 2022513490 A JP2022513490 A JP 2022513490A
Authority
JP
Japan
Prior art keywords
disease
syndrome
autoimmune
hla
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021534228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513490A5 (enExample
Inventor
オヒーロン、ピート
イチム、トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Figene LLC
Original Assignee
Figene LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Figene LLC filed Critical Figene LLC
Publication of JP2022513490A publication Critical patent/JP2022513490A/ja
Publication of JP2022513490A5 publication Critical patent/JP2022513490A5/ja
Priority to JP2024001373A priority Critical patent/JP2024041867A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2021534228A 2018-12-16 2019-12-16 遺伝子編集線維芽細胞の治療的使用 Pending JP2022513490A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024001373A JP2024041867A (ja) 2018-12-16 2024-01-09 遺伝子編集線維芽細胞の治療的使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862780289P 2018-12-16 2018-12-16
US62/780,289 2018-12-16
PCT/US2019/066575 WO2020131717A1 (en) 2018-12-16 2019-12-16 Therapeutic uses of gene edited fibroblasts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001373A Division JP2024041867A (ja) 2018-12-16 2024-01-09 遺伝子編集線維芽細胞の治療的使用

Publications (2)

Publication Number Publication Date
JP2022513490A true JP2022513490A (ja) 2022-02-08
JP2022513490A5 JP2022513490A5 (enExample) 2023-06-28

Family

ID=71102289

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021534228A Pending JP2022513490A (ja) 2018-12-16 2019-12-16 遺伝子編集線維芽細胞の治療的使用
JP2024001373A Pending JP2024041867A (ja) 2018-12-16 2024-01-09 遺伝子編集線維芽細胞の治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024001373A Pending JP2024041867A (ja) 2018-12-16 2024-01-09 遺伝子編集線維芽細胞の治療的使用

Country Status (6)

Country Link
US (1) US20220025332A1 (enExample)
EP (1) EP3894546A4 (enExample)
JP (2) JP2022513490A (enExample)
AU (1) AU2019403057B2 (enExample)
CA (1) CA3123408A1 (enExample)
WO (1) WO2020131717A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109837250B (zh) * 2019-01-15 2021-10-12 中国农业科学院兰州兽医研究所 羔羊睾丸支持细胞永生化细胞系及其建立方法和应用

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06506604A (ja) * 1991-07-15 1994-07-28 オクラホマ メディカル リサーチ ファウンデーション 自在なドナー細胞
JPH06319585A (ja) * 1992-11-26 1994-11-22 Fujisawa Pharmaceut Co Ltd 抗体およびその製造法
US5602307A (en) * 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
JPH09507753A (ja) * 1993-12-30 1997-08-12 セル ジェネシス，インコーポレイティド 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同組換え
JPH09512021A (ja) * 1994-04-19 1997-12-02 ザ ユニバーシティ オブ カンサス Ｉｃａｍ−１／ｌｆａ−１ 短鎖ペプチドおよび該ペプチドの使用方法
JP2002542200A (ja) * 1999-04-21 2002-12-10 久光製薬株式会社 免疫寛容を誘発するｄ型ポリペプチドおよびその使用方法
JP2003510046A (ja) * 1999-09-17 2003-03-18 リニューロン リミティッド 細胞の条件的不死化
US20030077565A1 (en) * 1993-01-21 2003-04-24 Bennett C. Frank Oligonucleotide modulation of cell adhesion
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
JP2008542252A (ja) * 2005-05-26 2008-11-27 インターサイテックス リミティド 同種真皮繊維芽細胞を用いる組織修復
JP2010511712A (ja) * 2006-12-04 2010-04-15 プロメディオール， インコーポレイテッド 線維症疾患を処置するための併用療法
CN104611370A (zh) * 2015-01-16 2015-05-13 深圳市科晖瑞生物医药有限公司 一种剔除β2-微球蛋白基因片段的方法
JP2016513460A (ja) * 2013-03-12 2016-05-16 サンガモ バイオサイエンシーズ， インコーポレイテッド Ｈｌａを修飾するための方法および組成物
JP2018500897A (ja) * 2014-12-10 2018-01-18 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 疾患を処置するための遺伝子改変された細胞、組織および臓器
JP2018515139A (ja) * 2015-05-08 2018-06-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 万能ドナー幹細胞および関連する方法
JP2018523977A (ja) * 2015-06-09 2018-08-30 エディタス・メディシン、インコーポレイテッド 移植を改善するためのｃｒｉｓｐｒ／ｃａｓ関連方法および組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939712B1 (en) * 1998-12-29 2005-09-06 Impedagen, Llc Muting gene activity using a transgenic nucleic acid
DE10049549A1 (de) * 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
AR080219A1 (es) * 2010-02-18 2012-03-21 Osiris Therapeutics Inc Productos de membranas corionicas inmunocompatibles
AU2016206870B2 (en) * 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06506604A (ja) * 1991-07-15 1994-07-28 オクラホマ メディカル リサーチ ファウンデーション 自在なドナー細胞
US5602307A (en) * 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
JPH06319585A (ja) * 1992-11-26 1994-11-22 Fujisawa Pharmaceut Co Ltd 抗体およびその製造法
US20030077565A1 (en) * 1993-01-21 2003-04-24 Bennett C. Frank Oligonucleotide modulation of cell adhesion
JPH09507753A (ja) * 1993-12-30 1997-08-12 セル ジェネシス，インコーポレイティド 普遍的なドナー細胞及びキメラ性哺乳類宿主のための相同組換え
JPH09512021A (ja) * 1994-04-19 1997-12-02 ザ ユニバーシティ オブ カンサス Ｉｃａｍ−１／ｌｆａ−１ 短鎖ペプチドおよび該ペプチドの使用方法
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
JP2002542200A (ja) * 1999-04-21 2002-12-10 久光製薬株式会社 免疫寛容を誘発するｄ型ポリペプチドおよびその使用方法
JP2003510046A (ja) * 1999-09-17 2003-03-18 リニューロン リミティッド 細胞の条件的不死化
JP2008542252A (ja) * 2005-05-26 2008-11-27 インターサイテックス リミティド 同種真皮繊維芽細胞を用いる組織修復
JP2010511712A (ja) * 2006-12-04 2010-04-15 プロメディオール， インコーポレイテッド 線維症疾患を処置するための併用療法
JP2016513460A (ja) * 2013-03-12 2016-05-16 サンガモ バイオサイエンシーズ， インコーポレイテッド Ｈｌａを修飾するための方法および組成物
JP2018500897A (ja) * 2014-12-10 2018-01-18 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 疾患を処置するための遺伝子改変された細胞、組織および臓器
CN104611370A (zh) * 2015-01-16 2015-05-13 深圳市科晖瑞生物医药有限公司 一种剔除β2-微球蛋白基因片段的方法
JP2018515139A (ja) * 2015-05-08 2018-06-14 プレジデント アンド フェローズ オブ ハーバード カレッジ 万能ドナー幹細胞および関連する方法
JP2018523977A (ja) * 2015-06-09 2018-08-30 エディタス・メディシン、インコーポレイテッド 移植を改善するためのｃｒｉｓｐｒ／ｃａｓ関連方法および組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ONCOIMMUNOLOGY, vol. 5, no. 3, JPN6023036564, 2016, pages 1091146 - 1, ISSN: 0005273005 *

Also Published As

Publication number Publication date
EP3894546A1 (en) 2021-10-20
EP3894546A4 (en) 2022-12-21
AU2019403057B2 (en) 2026-01-29
WO2020131717A1 (en) 2020-06-25
US20220025332A1 (en) 2022-01-27
CA3123408A1 (en) 2020-06-25
JP2024041867A (ja) 2024-03-27
AU2019403057A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
JP6560381B2 (ja) 脂肪組織または胎盤組織に由来する接着性細胞および治療におけるその使用
JP6830437B2 (ja) 疾患を処置するための遺伝子改変された細胞、組織および臓器
TWI863887B (zh) 使用具有工程化穩定表現內源性foxp3基因之cd4 t細胞治療自體免疫疾病的方法
ES2684599T3 (es) Células adherentes de la placenta y uso de las mismas en el tratamiento de enfermedades
ES2511791T3 (es) Células madre mesenquimales positivas para ABCB5 como moduladoras de inmunidad
McClain et al. In utero stem cell transplantation and gene therapy: Recent progress and the potential for clinical application
KR20200016954A (ko) 전신 면역억제가 불필요한 동종 이식편 내성
Deveza et al. Polymer-DNA nanoparticle-induced CXCR4 overexpression improves stem cell engraftment and tissue regeneration in a mouse hindlimb ischemia model
JP7555583B2 (ja) 母児間免疫寛容を誘導する方法
JP2022512674A (ja) 人工トランス活性化因子による選択
JP2024041867A (ja) 遺伝子編集線維芽細胞の治療的使用
US20190076479A1 (en) Adipose tissue-derived stem cells from transgenic porcine animals for human use
US20250375520A1 (en) Production of immune cells
Surbek et al. Perinatal stem-cell and gene therapy for hemoglobinopathies
Shear et al. In utero fetal therapy: Stem cells, cell transplantation, gene therapy, and CRISPR-Cas9
KR20180079033A (ko) Igf-1 및 il-10을 분비하는 세포, 및 이의 용도
Almeida-Porada et al. Prenatal cell-and gene-based therapies for regenerative medicine
Lehner “A” Study on the Efficacy of a Lentiviral Vector for Treatment of Immunodeficiency in a Mouse Disease Model
JP2023099685A (ja) 養子免疫療法における腫瘍フレアを管理する方法
JP2026504480A (ja) Ｋｒａｓ結合タンパク質と内在性ｔｃｒのノックアウトとを有する宿主細胞、およびその使用方法
WO2026068582A1 (en) Means and methods for modulating immune responses
JP2025508965A (ja) 萎縮した脾臓の再生と修復を刺激する線維芽細胞の治療的使用
CN115803436A (zh) 免疫原性降低的新型移植细胞
Winterhalter CRISPR/Cas9 based HLA reduction of T cells for universal T cell therapy
JPWO1999003980A1 (ja) Ａｇｍ領域由来ストローマ細胞

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230620

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240110

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240130

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240308